Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "gut microbiome restoration" does not refer to a specific molecule or receptor but rather describes therapeutic strategies aimed at re-establishing a healthy balance and diversity within the gut microbial community. The gut microbiome is an ecosystem composed primarily of bacteria but also includes viruses, fungi, archaea and other microorganisms that inhabit the gastrointestinal tract. These microbes play essential roles in digestion; synthesis of vitamins; production of short-chain fatty acids; metabolism; maintenance of the intestinal barrier; modulation of immune responses; and protection against pathogens. Disruption to this ecosystem—through antibiotics use, illness or other factors—can lead to dysbiosis associated with various diseases including recurrent Clostridioides difficile infection (*C. diff*), inflammatory conditions and even neurodegenerative disorders. Restoration approaches include fecal microbiota transplantation (FMT), administration of defined microbial consortia such as SER‑109 or RBX2660 capsules/enemas derived from healthy donors’ stool samples as well as dietary interventions using prebiotic fibers. While these therapies have shown efficacy in treating recurrent *C. diff* infections by restoring microbial diversity that suppresses pathogen overgrowth,[1][3][5] they are not molecular targets themselves but rather broad ecological interventions. Safety concerns include risk for transmission of infectious agents from donor material,[1][3] lack standardization across products,[3] variable efficacy depending on patient population/study design,[3] and incomplete understanding regarding long-term effects. Because "gut microbiome restoration" is not a single molecule/receptor/target classifiable under conventional pharmacological categories like "receptor," "enzyme," etc., it should be considered an incorrect entry if used as a drug target name.[2][4]
Restoration or modulation of microbial diversity to outcompete pathogenic bacteria and restore metabolic/immune homeostasis[1][3][5]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiome.